Abstract
2-(2′,4′-Dibromophenoxy)-4,6-dibromophenol isolated from the marine sponge Dysidea granulosa (Bergquist) collected off the coast of Lakshadweep islands, Indian Ocean, exhibited potent and broad spectrum in-vitro antibacterial activity, especially against methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive Staphylococcus aureus (MSSA), vancomycin resistant Enterococci (VRE), vancomycin sensitive Enterococci (VSE) and Bacillus spp. Minimal inhibitory concentration (MIC) was evaluated against 57 clinical and standard strains of Gram positive and Gram negative bacteria. The observed MIC range was 0.117–2.5 μg/mL against all the Gram positive bacteria and 0.5–2 μg/mL against Gram negative bacteria. The in-vitro antibacterial activity observed was better than that of the standard antibiotic linezolid, a marketed anti-MRSA drug. The results establish 2-(2′,4′-dibromophenoxy)-4,6-dibromophenol, as a potential lead molecule for anti-MRSA and anti-VRE drug development.
Highlights
The striking rise in the prevalence of bacterial antibiotic resistance currently poses a serious threat to public health worldwide
The most significant problem in clinical practice is the increase in incidence of methicillin resistant Staphylococcus aureus (MRSA) infections
The appearance of vancomycin resistant Enterococci (VRE) infections has caused a dilemma upon physicians – linezolid and streptogramin combinations are the new drugs of choice for treating MRSA infections, but linezolid resistance have been reported in VRE and MRSA isolates [4]
Summary
The striking rise in the prevalence of bacterial antibiotic resistance currently poses a serious threat to public health worldwide. The appearance of vancomycin resistant Enterococci (VRE) infections has caused a dilemma upon physicians – linezolid and streptogramin combinations are the new drugs of choice for treating MRSA infections, but linezolid resistance have been reported in VRE and MRSA isolates [4]. MRSA and other S. aureus strains have been reported to acquire resistance to the last-resort antibiotic, vancomycin [8,9]. 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol from a new source D. granulosa, its potent in-vitro antibacterial activity, and as a possible lead molecule for drug development especially against strains of MRSA, methicillin sensitive S. aureus (MSSA), VRE and vancomycin sensitive Enterococci (VSE)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
